Bank of New York Mellon’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-191,432
| Closed | -$3.01M | – | 4314 |
|
|
2024
Q1 | $3.01M | Sell |
191,432
-10,882
| -5% | -$167K | ﹤0.01% | 2552 |
|
|
2023
Q4 | $3.26M | Sell |
202,314
-2,338
| -1% | -$29.8K | ﹤0.01% | 2582 |
|
|
2023
Q3 | $2.6M | Sell |
204,652
-223
| -0.1% | -$3.08K | ﹤0.01% | 2661 |
|
|
2023
Q2 | $2.88M | Buy |
204,875
+15,051
| +8% | +$215K | ﹤0.01% | 2632 |
|
|
2023
Q1 | $2.93M | Buy |
189,824
+14,317
| +8% | +$239K | ﹤0.01% | 2585 |
|
|
2022
Q4 | $2.88M | Buy |
175,507
+5,579
| +3% | +$90.7K | ﹤0.01% | 2647 |
|
|
2022
Q3 | $3.14M | Buy |
169,928
+18,166
| +12% | +$285K | ﹤0.01% | 2556 |
|
|
2022
Q2 | $2M | Buy |
151,762
+8,264
| +6% | +$91.2K | ﹤0.01% | 2833 |
|
|
2022
Q1 | $1.33M | Buy |
143,498
+6,460
| +5% | +$54.9K | ﹤0.01% | 3136 |
|
|
2021
Q4 | $1.34M | Sell |
137,038
-29,750
| -18% | -$559K | ﹤0.01% | 3218 |
|
|
2021
Q3 | $5.67M | Buy |
166,788
+8,497
| +5% | +$271K | ﹤0.01% | 2423 |
|
|
2021
Q2 | $5.79M | Sell |
158,291
-23,223
| -13% | -$899K | ﹤0.01% | 2414 |
|
|
2021
Q1 | $8.14M | Sell |
181,514
-6,126
| -3% | -$285K | ﹤0.01% | 2206 |
|
|
2020
Q4 | $10.7M | Buy |
187,640
+14,314
| +8% | +$848K | ﹤0.01% | 1967 |
|
|
2020
Q3 | $8.89M | Buy |
173,326
+3,836
| +2% | +$188K | ﹤0.01% | 1916 |
|
|
2020
Q2 | $10.1M | Buy |
169,490
+48,493
| +40% | +$2.59M | ﹤0.01% | 1826 |
|
|
2020
Q1 | $4.98M | Buy |
120,997
+4,503
| +4% | +$250K | ﹤0.01% | 2075 |
|
|
2019
Q4 | $7.25M | Buy |
116,494
+19,802
| +20% | +$941K | ﹤0.01% | 2149 |
|
|
2019
Q3 | $3.28M | Buy |
96,692
+38,224
| +65% | +$1.13M | ﹤0.01% | 2485 |
|
|
2019
Q2 | $1.32M | Buy |
58,468
+11,342
| +24% | +$265K | ﹤0.01% | 3046 |
|
|
2019
Q1 | $1.09M | Buy |
47,126
+422
| +0.9% | +$11K | ﹤0.01% | 3112 |
|
|
2018
Q4 | $981K | Sell |
46,704
-19,704
| -30% | -$484K | ﹤0.01% | 3117 |
|
|
2018
Q3 | $2.57M | Buy |
66,408
+9,966
| +18% | +$368K | ﹤0.01% | 2715 |
|
|
2018
Q2 | $2.22M | Buy |
56,442
+32,878
| +140% | +$968K | ﹤0.01% | 2795 |
|
|
2018
Q1 | $472K | Buy |
23,564
+6,479
| +38% | +$164K | ﹤0.01% | 3615 |
|
|
2017
Q4 | $388K | Buy |
+17,085
| New | +$335K | ﹤0.01% | 3718 |
|
Other funds holding DCPH
Bank of New York Mellon's DCPH Position: Q2 2024 in Review
Bank of New York Mellon sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 191,432 shares — an estimated $3.01M sold.
Bank of New York Mellon first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $10.7M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Bank of New York Mellon reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Bank of New York Mellon sold 191,432 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $3.01M.
- Bank of New York Mellon first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
- Bank of New York Mellon's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $10.7M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.